

REMARKS**1. Claims Amendments.**

Claim 1 has been amended to delete "prophylaxis or" to address the examiner's concern under 35 USC 112, 1st paragraph.

Claims 2-3 have not been amended in this response.

Claims 4-7 have been amended to delete "prophylaxis or" to address the examiner's concern under 35 USC 112, 1st paragraph.

Claims 8, 10, 12, 14, and 16 have been amended to include "mixture" to correct the antecedent basis issue under 35 USC 112, 2nd paragraph in these claims.

Claims 9, 11, 13, and 17 have been amended to delete "based sophorolipid" to clarify the claims based on the above amendments to Claims 8, 10, 12, 14, and 16.

Claim 15 has been cancelled.

Claims 18-26 have not been amended in this response.

Claims 27-33 previously have been withdrawn.

Claim 34 has been amended to delete "prophylaxis or" to address the examiner's concern under 35 USC 112, 1st paragraph and to include the steps for the application of the sophorolipids to address the examiner's concern under 35 USC 112, 2nd paragraph.

Claim 35 has been amended to delete "prophylaxis or" to address the examiner's concern under 35 USC 112, 1st paragraph.

No new matter has been entered in any of the above amendments to the claims. Further, each of the amendments is to address technicalities

2. The Claims Satisfy 35 USC 112.

Claims 33-34 [sic] (we assume the examiner meant 34-35) were rejected for omitting essential steps. Although Applicant meant an overall use of the composition of the invention in the use of the term "application" in the preamble of Claim 34, Applicant has amended Claim 34 to include the sequences of steps from original Claims 4-7 to address the examiner's concern under 35 USC 112, 2nd paragraph. No new matter has been added and these claims now satisfy 35 USC 112.

Claims 8-17 were rejected for including the limitation "sophorolipid" when the base claim included the element "sophorolipid mixture". These claims have been amended to address this issue under 35 USC 112, 2nd paragraph, and to clarify the language, specifically the preferred 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate. No new matter has been added and these claims now satisfy 35 USC 112.


Claims 1-26, 33, and 34 [sic] (we assume the examiner meant 1-26, 34, and 35) were rejected for not being enabling for "prophylaxis". Applicant has deleted "prophylaxis" from all of the claims to address the examiner's concern under 35 USC 112, 1st paragraph. No new matter has been added and these claims now satisfy 35 USC 112.

Claim 34 was rejected as being anticipated by the Davila reference. The amendment to Claim 34 to include the steps for the application of the compounds of the present invention overcome this rejection, as the Davila reference does not disclose or even refer to the use of sophorolipids to treat sepsis or septic shock, and this claim now satisfies 35 USC 102.

CONCLUSION

The patent application now is in condition for allowance and Applicant requests such action. If the examiner has any questions or concerns that can be addressed over the telephone, please have the examiner contact the below-signed attorney of record.

Respectfully submitted,
POWELL GOLDSTEIN LLP



Laurence P. Colton
Reg. No. 33,371

POWELL GOLDSTEIN LLP
One Atlantic Center, Fourteenth Floor
1201 West Peachtree Street, NW
Atlanta GA 30309-3488 US

Tel: 404.572.6710
Fax: 404.572.6999
E-Mail: lcolton@pogolaw.com